Dual Frequency Stimulation in Parkinson's Disease
NCT: NCT04650932 · RECRUITING
Brief Summary
Deep brain stimulation (DBS) in the dorsal region of the subthalamic nucleus (STN) is very effective for reducing motor symptoms of Parkinson's disease (PD). Modeling studies suggest that this therapy may result in current spread into the ventral STN, causing altered cognitive processes. As a result, current stimulation parameters often lead to worsening in verbal fluency, executive function, and, particularly, cognitive control. There is evidence suggesting that low frequency oscillatory activity occurs across brain circuits important in integrating information for cognition. Preclinical studies and human recording studies indicate these low frequency theta oscillations drive cognitive control during cognitive tasks. Thus, the purpose of this study is to determine the safety, tolerability, and efficacy of low frequency stimulation (LFS) of the ventral STN alongside standard high frequency stimulation (HFS) of the dorsal STN in patients with PD.
Frequently Asked Questions
What is Dual Frequency Stimulation in Parkinson's Disease?
Dual Frequency Stimulation in Parkinson's Disease is a clinical trial registered under NCT04650932. Current status: RECRUITING.
What is the status of NCT04650932?
The current status of NCT04650932 (Dual Frequency Stimulation in Parkinson's Disease) is: RECRUITING.
When did Dual Frequency Stimulation in Parkinson's Disease start?
Dual Frequency Stimulation in Parkinson's Disease started on 2022-10-22.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.